Perceptive Advisors - Q3 2022 holdings

$3.45 Billion is the total value of Perceptive Advisors's 116 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 26.1% .

 Value Shares↓ Weighting
FOLD BuyAMICUS THERAPEUTICS INC$285,773,000
-1.1%
27,372,917
+1.8%
8.29%
-8.3%
MRTX SellMIRATI THERAPEUTICS INC$194,490,000
+1.1%
2,784,796
-2.9%
5.64%
-6.4%
CERE BuyCEREVEL THERAPEUTICS HLDNG I$184,021,000
+36.8%
6,511,727
+28.0%
5.34%
+26.8%
GBT SellGLOBAL BLOOD THERAPEUTICS IN$158,145,000
+64.2%
2,322,247
-23.0%
4.59%
+52.1%
BuyAMYLYX PHARMACEUTICALS INC$154,038,000
+125.9%
5,472,033
+54.6%
4.47%
+109.3%
BuyLIANBIOsponsored ads$115,116,000
-5.8%
57,558,451
+1.8%
3.34%
-12.7%
BuyCINCOR PHARMA INC$108,524,000
+148.4%
3,306,649
+42.6%
3.15%
+130.3%
BLU BuyBELLUS HEALTH INC NEW$108,209,000
+111.6%
10,247,073
+85.2%
3.14%
+96.0%
CRNX  CRINETICS PHARMACEUTICALS IN$104,505,000
+5.3%
5,321,0320.0%3.03%
-2.4%
SWTX SellSPRINGWORKS THERAPEUTICS INC$99,015,000
+4.0%
3,470,563
-10.3%
2.87%
-3.6%
IOVA SellIOVANCE BIOTHERAPEUTICS INC$98,181,000
-24.8%
10,248,624
-13.3%
2.85%
-30.3%
RLMD BuyRELMADA THERAPEUTICS INC$88,236,000
+3729.7%
2,383,478
+1864.1%
2.56%
+3456.9%
RXDX SellPROMETHEUS BIOSCIENCES INC$86,657,000
+82.5%
1,468,512
-12.7%
2.52%
+69.1%
XENE  XENON PHARMACEUTICALS INC$76,624,000
+18.7%
2,122,5350.0%2.22%
+10.0%
ALDX BuyALDEYRA THERAPEUTICS INC$60,609,000
+53.4%
11,350,085
+14.6%
1.76%
+42.1%
MGTX  MEIRAGTX HLDGS PLC$58,561,000
+11.1%
6,963,2770.0%1.70%
+3.0%
INBX BuyINHIBRX INC$51,837,000
+138.5%
2,887,860
+50.8%
1.50%
+120.9%
VRNA BuyVERONA PHARMA PLCsponsored ads$51,583,000
+322.3%
5,047,264
+73.1%
1.50%
+290.9%
COGT BuyCOGENT BIOSCIENCES INC$47,855,000
+71.8%
3,207,441
+3.8%
1.39%
+59.1%
BuyARCELLX INC$46,276,000
+124.1%
2,465,405
+115.9%
1.34%
+107.6%
 TRAVERE THERAPEUTICS INCnote 2.250% 3/0$45,980,000
-89.9%
45,000,0000.0%1.33%
-90.7%
LYRA  LYRA THERAPEUTICS INC$45,825,000
-11.3%
9,146,7300.0%1.33%
-17.9%
ALBO  ALBIREO PHARMA INC$45,692,000
-2.5%
2,360,1390.0%1.33%
-9.7%
VERU BuyVERU INC$44,847,000
+13.4%
3,893,000
+11.2%
1.30%
+5.1%
RLAY  RELAY THERAPEUTICS INC$43,467,000
+33.6%
1,943,0970.0%1.26%
+23.7%
SGEN BuySEAGEN INC$43,313,000
+9.3%
316,544
+41.3%
1.26%
+1.3%
RAPT SellRAPT THERAPEUTICS INC$41,218,000
+18.0%
1,713,134
-10.5%
1.20%
+9.3%
VBIV  VBI VACCINES INC CDA$37,157,000
-12.2%
52,335,0020.0%1.08%
-18.6%
TMCI BuyTREACE MED CONCEPTS INC$35,356,000
+162.0%
1,601,979
+70.2%
1.03%
+142.6%
 NUVALENT INC$32,173,000
+43.4%
1,655,0070.0%0.93%
+32.9%
ESTA BuyESTABLISHMENT LABS HLDGS INC$31,578,000
+43.1%
578,253
+42.5%
0.92%
+32.6%
BMRN BuyBIOMARIN PHARMACEUTICAL INC$28,523,000
+91.2%
336,481
+86.9%
0.83%
+77.3%
SRPT NewSAREPTA THERAPEUTICS INC$27,967,000253,000
+100.0%
0.81%
EW NewEDWARDS LIFESCIENCES CORP$27,268,000330,000
+100.0%
0.79%
ZYME BuyZYMEWORKS INC$27,060,000
+23.6%
4,400,099
+6.5%
0.78%
+14.4%
ADMA SellADMA BIOLOGICS INC$26,568,000
+16.5%
10,933,387
-5.1%
0.77%
+8.0%
VRDN BuyVIRIDIAN THERAPEUTICS INC$25,034,000
+122.6%
1,220,575
+25.6%
0.73%
+106.5%
APLS BuyAPELLIS PHARMACEUTICALS INC$25,025,000
+72.2%
366,400
+14.0%
0.73%
+59.6%
IMTX  IMMATICS N.V$25,000,000
+14.8%
2,500,0000.0%0.73%
+6.5%
CMAX BuyCAREMAX INC$24,070,000
+121.0%
3,394,939
+13.2%
0.70%
+105.0%
TARS  TARSUS PHARMACEUTICALS INC$22,194,000
+17.3%
1,296,4160.0%0.64%
+8.6%
RVNC BuyREVANCE THERAPEUTICS INC$21,834,000
+176.0%
808,671
+41.2%
0.63%
+155.6%
MDGL SellMADRIGAL PHARMACEUTICALS INC$21,513,000
-18.2%
331,023
-9.9%
0.62%
-24.3%
NAUT  NAUTILUS BIOTECHNOLOGY INC$19,315,000
-21.2%
9,111,1510.0%0.56%
-27.0%
NewCYTEK BIOSCIENCES INC$18,982,0001,289,534
+100.0%
0.55%
OM BuyOUTSET MED INC$18,616,000
+25.4%
1,168,630
+17.0%
0.54%
+16.1%
ISEE SellIVERIC BIO INC$18,553,000
-7.6%
1,034,169
-50.5%
0.54%
-14.5%
HRMY  HARMONY BIOSCIENCES HLDGS IN$18,239,000
-9.2%
411,8040.0%0.53%
-15.9%
RCUS NewARCUS BIOSCIENCES INC$17,435,000666,477
+100.0%
0.51%
BBIO  BRIDGEBIO PHARMA INC$16,869,000
+9.5%
1,697,0330.0%0.49%
+1.4%
CRY BuyARTIVION INC$16,667,000
-5.0%
1,204,229
+29.5%
0.48%
-12.0%
CHRS SellCOHERUS BIOSCIENCES INC$16,021,000
-39.3%
1,667,123
-54.3%
0.46%
-43.8%
VRCA  VERRICA PHARMACEUTICALS INC$14,714,000
+52.1%
5,038,9830.0%0.43%
+40.9%
AKRO NewAKERO THERAPEUTICS INC$14,642,000430,000
+100.0%
0.42%
CNCE  CONCERT PHARMACEUTICALS INC$14,409,000
+59.1%
2,150,6410.0%0.42%
+47.2%
ATHA  ATHIRA PHARMA INC$14,248,000
-2.6%
4,797,2780.0%0.41%
-9.6%
PRTA NewPROTHENA CORP PLC$13,945,000230,000
+100.0%
0.40%
SellDICE THERAPEUTICS INC$13,941,000
-14.6%
687,424
-34.6%
0.40%
-20.7%
 HILLEVAX INC$13,072,000
+56.4%
764,9070.0%0.38%
+44.7%
RAIN  RAIN THERAPEUTICS INC$12,120,000
-12.2%
2,483,6190.0%0.35%
-18.7%
 ASTRIA THERAPEUTICS INC$11,582,000
+201.4%
1,281,1970.0%0.34%
+180.0%
AXGN NewAXOGEN INC$11,320,000949,626
+100.0%
0.33%
SellPROCEPT BIOROBOTICS CORP$10,934,000
-55.4%
263,720
-64.8%
0.32%
-58.7%
NBIX SellNEUROCRINE BIOSCIENCES INC$10,626,000
-72.6%
100,050
-74.9%
0.31%
-74.7%
MORF  MORPHIC HLDG INC$10,278,000
+30.4%
363,1970.0%0.30%
+20.6%
CCXI SellCHEMOCENTRYX INC$9,954,000
-9.1%
192,680
-56.4%
0.29%
-15.7%
LABP  LANDOS BIOPHARMA INC$9,665,000
-10.7%
14,869,9150.0%0.28%
-17.4%
LRMR NewLARIMAR THERAPEUTICS INC$9,152,0002,860,000
+100.0%
0.27%
OMIC  SINGULAR GENOMICS SYSTEMS IN$8,841,000
-34.6%
3,536,2740.0%0.26%
-39.2%
RCKT SellROCKET PHARMACEUTICALS INC$7,980,000
-50.3%
500,000
-57.2%
0.23%
-53.9%
KRON SellKRONOS BIO INC$7,223,000
-18.0%
2,156,151
-10.9%
0.21%
-23.9%
 ISOPLEXIS CORP$7,044,000
-20.4%
4,095,4980.0%0.20%
-26.4%
NVRO NewNEVRO CORP$6,990,000150,000
+100.0%
0.20%
CCCC  C4 THERAPEUTICS INC$6,720,000
+16.3%
766,2310.0%0.20%
+7.7%
LPTX SellLEAP THERAPEUTICS INC$6,575,000
-28.1%
7,472,148
-6.0%
0.19%
-33.2%
SLDB  SOLID BIOSCIENCES INC$6,258,000
-24.2%
13,412,5520.0%0.18%
-29.7%
RVMD NewREVOLUTION MEDICINES INC$6,123,000310,500
+100.0%
0.18%
ACRS  ACLARIS THERAPEUTICS INC$5,371,000
+12.7%
341,2390.0%0.16%
+4.7%
NTRA NewNATERA INC$5,258,000120,000
+100.0%
0.15%
TCDA NewTRICIDA INCput$5,240,000500,000
+100.0%
0.15%
NARI NewINARI MED INC$5,085,00070,000
+100.0%
0.15%
 ENVVENO MEDICAL CORPORATION$4,909,000
+66.2%
781,6150.0%0.14%
+52.7%
 SEMA4 HOLDINGS CORP$4,390,000
-30.3%
5,000,0000.0%0.13%
-35.5%
 SOMALOGIC INC$4,350,000
-35.8%
1,500,0000.0%0.13%
-40.6%
 TYRA BIOSCIENCES INC$4,346,000
+22.9%
494,4030.0%0.13%
+13.5%
CTIC NewCTI BIOPHARMA CORP$4,279,000735,165
+100.0%
0.12%
ATNX BuyATHENEX INC$4,178,000
-24.6%
15,532,467
+14.8%
0.12%
-30.5%
ABOS SellACUMEN PHARMACEUTICALS INC$4,012,000
+67.9%
400,000
-21.3%
0.12%
+54.7%
PNT SellPOINT BIOPHARMA GLOBAL INC$3,865,000
-47.2%
500,000
-53.4%
0.11%
-51.1%
HCAT SellHEALTH CATALYST INC$3,783,000
-43.9%
389,962
-16.2%
0.11%
-47.9%
NBTX  NANOBIOTIXsponsored ads$3,752,000
-6.8%
1,059,8000.0%0.11%
-13.5%
 COHERUS BIOSCIENCES INCnote 1.500% 4/1$3,592,000
-87.8%
4,500,0000.0%0.10%
-88.7%
YMAB  Y-MABS THERAPEUTICS INC$3,057,000
-4.7%
212,0180.0%0.09%
-11.0%
 PYXIS ONCOLOGY INC$3,012,000
-17.2%
1,528,8120.0%0.09%
-23.7%
 ABSCI CORPORATION$2,799,000
-5.7%
894,3460.0%0.08%
-12.9%
PSTX NewPOSEIDA THERAPEUTICS INC$2,648,000750,000
+100.0%
0.08%
CLOV  CLOVER HEALTH INVESTMENTS CO$2,550,000
-20.6%
1,500,0000.0%0.07%
-26.7%
RETA NewREATA PHARMACEUTICALS INCcl a$2,513,000100,000
+100.0%
0.07%
QTNT  QUOTIENT LTD$2,430,000
-37.5%
16,200,8180.0%0.07%
-41.8%
 SCIENCE 37 HOLDINGS INC$2,415,000
-19.9%
1,500,0000.0%0.07%
-25.5%
FULC  FULCRUM THERAPEUTICS INC$2,379,000
+65.1%
294,1180.0%0.07%
+53.3%
TVTX SellTRAVERE THERAPEUTICS INC$2,236,000
-83.8%
90,748
-84.1%
0.06%
-85.0%
 PEAR THERAPEUTICS INC$1,837,000
+32.5%
900,5480.0%0.05%
+23.3%
 DARIOHEALTH CORP$1,518,000
-24.6%
327,8690.0%0.04%
-30.2%
TARA  PROTARA THERAPEUTICS INC$859,000
+1.1%
290,0510.0%0.02%
-7.4%
SellHYPERFINE INC$751,000
-70.3%
927,388
-18.2%
0.02%
-72.2%
SellSONENDO INC$655,000
-41.3%
612,204
-5.6%
0.02%
-45.7%
PRVB  PROVENTION BIO INC$498,000
+12.4%
110,7280.0%0.01%0.0%
SellICOSAVAX INC$296,000
-95.0%
93,591
-91.0%
0.01%
-95.2%
 EQRX INC*w exp 12/17/202$205,000
+1.0%
250,0000.0%0.01%0.0%
NewMOTUS GI HLDGS INC$221,00090,027
+100.0%
0.01%
 AGILE THERAPEUTICS INC$158,000
-74.5%
532,3610.0%0.01%
-73.7%
CMAXW  CAREMAX INC*w exp 06/08/202$113,000
+162.8%
60,0000.0%0.00%
+200.0%
 NEPTUNE WELLNESS SOLUTIONS I$87,000
+7.4%
57,1420.0%0.00%0.0%
 SURROZEN INC*w exp 08/01/203$31,000
-3.1%
166,6660.0%0.00%0.0%
 SURROZEN INC$12,000
-33.3%
6,0170.0%0.00%
-100.0%
MOTS ExitMOTUS GI HLDGS INC$0-1,800,542
-100.0%
-0.02%
ZY ExitZYMERGEN INC$0-883,332
-100.0%
-0.03%
RACE ExitFERRARI N V$0-6,200
-100.0%
-0.04%
FUSN ExitFUSION PHARMACEUTICALS INC$0-1,052,445
-100.0%
-0.08%
SAVA ExitCASSAVA SCIENCES INCput$0-100,000
-100.0%
-0.09%
MGNX ExitMACROGENICS INC$0-1,227,202
-100.0%
-0.11%
NUVB ExitNUVATION BIO INC$0-1,769,701
-100.0%
-0.18%
XBI ExitSPDR SER TRput$0-100,000
-100.0%
-0.23%
PRVA ExitPRIVIA HEALTH GROUP INC$0-273,423
-100.0%
-0.25%
DAWN ExitDAY ONE BIOPHARMACEUTICALS I$0-556,047
-100.0%
-0.31%
ALNY ExitALNYLAM PHARMACEUTICALS INC$0-172,991
-100.0%
-0.79%
LLY ExitLILLY ELI & CO$0-100,000
-100.0%
-1.02%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-11-14
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q3 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
42024-02-21
42024-02-20
13F-HR2024-02-14
SC 13D/A2024-02-14
SC 13D/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Perceptive Advisors's complete filings history.

Compare quarters

Export Perceptive Advisors's holdings